The FDA cleared Fresenius Kabi’s plasma collection system that accelerates the plasma collection process, facilitating plasma donation for donors and center operators alike.
Plasma is used in the treatment of burn victims as well as people with bleeding disorders and human immune deficiencies. In plasma donation, a plasmapheresis system draws whole blood via a needle in a donor’s vein. It then separates the plasma from the red blood cells and other cellular components, which are then returned to the donor’s body.
Fresenius Kabi’s Aurora Xi Plasmapheresis System has a proprietary filtration-separation method that allows it to collect plasma faster, according to a statement.
“Faster collection times mean more throughput for our customers, helping maximize the volumes of plasma they collect while assuring a good experience for plasma donors,” said Dean Gregory, president Fresenius Kabi USA’s medical devices unit, in the statement.
In addition to its plasmapheresis offerings, Fresenius Kabi markets pharmaceuticals and tech for infusion, transfusion and clinical nutrition for the care of critically and chronically ill patients. These include cell separators and intravenous solutions.